{
    "clinical_study": {
        "@rank": "94135", 
        "acronym": "PUCHS", 
        "arm_group": {
            "arm_group_label": "Retrospective collection of data"
        }, 
        "brief_summary": {
            "textblock": "This study is conducted in Europe. The aim of the study is to update the knowledge about the\n      prevalence and severity of congenital haemophilia (A and B) in Spain."
        }, 
        "brief_title": "Project to Update the Study of Congenital Haemophilia in Spain", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Congenital Bleeding Disorder", 
            "Haemophilia A", 
            "Haemophilia B"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Blood Coagulation Disorders", 
                "Hemostatic Disorders", 
                "Hemorrhagic Disorders", 
                "Hemophilia B", 
                "Hemophilia A", 
                "Hemorrhage"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed consent obtained before any study-related activities. (Study-related\n             activities are any procedure related to recording of data according to the protocol)\n\n          -  Male patients of any age diagnosed with congenital haemophilia A or B who visited\n             their HTC at least once during the period of January 2013 to December 2013\n\n        Exclusion Criteria:\n\n          -  Previous participation in this study\n\n          -  Female patients\n\n          -  Acquired haemophilia"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients in active follow-up in HTCs (Haemophilia Treatment Centres) will be included in\n        this study. A patient is considered as active if a visit to the HTC is performed in the\n        period of January 2013 to December 2013."
            }
        }, 
        "enrollment": {
            "#text": "2500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01959555", 
            "org_study_id": "HAEM-4076", 
            "secondary_id": [
                "U1111-1147-5668", 
                "NOV-HEM-2013-01"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Retrospective collection of data", 
            "description": "Patients will not be treated with any specific product. Data collection only.", 
            "intervention_name": "No treatment given", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 19, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Madrid", 
                    "country": "Spain", 
                    "zip": "28033"
                }
            }
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_groups": "1", 
        "official_title": "Project to Update the Study of Congenital Haemophilia in Spain", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Prevalence of congenital haemophilia A and B in Spain in 2013, described as proportion (%) of patients in the total population (extracted from the last available census of the Spanish population for the regions considered for the study)", 
                "safety_issue": "No", 
                "time_frame": "Assessed at study visit (day 1)"
            }, 
            {
                "measure": "Severity (mild, moderate or severe) of congenital haemophilia A and B in Spain during 2013, described as proportion (%) per category of the total number of patients with haemophilia A or B", 
                "safety_issue": "No", 
                "time_frame": "Assessed at study visit (day 1)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01959555"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mean current age at the time of visit to the HTC in 2013", 
                "safety_issue": "No", 
                "time_frame": "Assessed at study visit (day 1)"
            }, 
            {
                "measure": "Mean age at diagnosis", 
                "safety_issue": "No", 
                "time_frame": "Assessed at study visit (day 1)"
            }, 
            {
                "measure": "Proportion (%) of patients with/without genetic screening performed", 
                "safety_issue": "No", 
                "time_frame": "Assessed at study visit (day 1)"
            }, 
            {
                "measure": "Proportion (%) of patients who needed support of a reference Haemophilia Healthcare Centre in 2013", 
                "safety_issue": "No", 
                "time_frame": "Assessed at study visit (day 1)"
            }, 
            {
                "measure": "Proportion (%) of patients who received plasmatic or recombinant treatment", 
                "safety_issue": "No", 
                "time_frame": "Assessed at study visit (day 1)"
            }, 
            {
                "measure": "Proportion (%) of patients who received on demand or prophylaxis treatment", 
                "safety_issue": "No", 
                "time_frame": "Assessed at study visit (day 1)"
            }, 
            {
                "measure": "Mean number of bleeding episodes", 
                "safety_issue": "No", 
                "time_frame": "Assessed at study visit (day 1)"
            }, 
            {
                "measure": "Mean number of joint bleeds", 
                "safety_issue": "No", 
                "time_frame": "Assessed at study visit (day 1)"
            }, 
            {
                "measure": "Proportion (%) of patients with established arthropathy", 
                "safety_issue": "No", 
                "time_frame": "Assessed at study visit (day 1)"
            }, 
            {
                "measure": "Proportion (%) of patients with infectious complications", 
                "safety_issue": "No", 
                "time_frame": "Assessed at study visit (day 1)"
            }, 
            {
                "measure": "Proportion (%) of patients with HIV (Human immunodeficiency virus)", 
                "safety_issue": "No", 
                "time_frame": "Assessed at study visit (day 1)"
            }, 
            {
                "measure": "Proportion (%) of patients with presence of inhibitors", 
                "safety_issue": "No", 
                "time_frame": "Assessed at study visit (day 1)"
            }, 
            {
                "measure": "Proportion (%) of patients with immune tolerance induction treatment performed", 
                "safety_issue": "No", 
                "time_frame": "Assessed at study visit (day 1)"
            }, 
            {
                "measure": "Total number of surgery interventions performed", 
                "safety_issue": "No", 
                "time_frame": "ThAssessed at study visit (day 1)"
            }, 
            {
                "measure": "Proportion (%) of patients with quality of life questionnaire (QoLQ) performed in 2013", 
                "safety_issue": "No", 
                "time_frame": "Assessed at study visit (day 1)"
            }, 
            {
                "measure": "Mean number of days of absenteeism to school/university in children and adolescents in 2013", 
                "safety_issue": "No", 
                "time_frame": "Assessed at study visit (day 1)"
            }, 
            {
                "measure": "Mean number of days of absenteeism from work in 2013", 
                "safety_issue": "No", 
                "time_frame": "Assessed at study visit (day 1)"
            }, 
            {
                "measure": "Proportion (%) of patients with treatment administered at home", 
                "safety_issue": "No", 
                "time_frame": "Assessed at study visit (day 1)"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}